iScience Interventional Announces Clinical and Commercial Supply Agreement iScience Interventional announced it has signed a clinical and commercial supply agreement with Johnson & Johnson Pharmaceutical Research & Development, LLC., and its affiliates. [MarketWatch] Press ReleaseServier and Miragen Sign $352 Million Partnership Agreement for the Research, Development and Commercialization of MicroRNA-targeting Drugs for Cardiovascular Disease Les Laboratoires Servier and Miragen Therapeutics, Inc. announced an agreement for advancing the research, development and commercialization of three drug candidates, including two of miRagen’s lead programs (miR-208 and miR-15/195) and one additional target yet to be identified, for cardiovascular disease. [Miragen Therapeutics, Inc.] Press Release Otsuka Commits $ 25 Million to JV with LCT Living Cell Technologies Limited (LCT) has agreed to establish a 50/50 joint venture company DIATRANZ OTSUKA LIMITED with Otsuka Pharmaceutical Factory, Inc. to accelerate the commercialization of LCT’s DIABECELL®, a ground breaking new cell implant therapy to treat diabetes. [Living Cell Technologies Limited] Press Release RetroSense Licenses Gene Therapy for Restoring Vision from Wayne State University RetroSense Therapeutics has taken up its option to acquire an exclusive global license to a gene-based approach to treating retinitis pigmentosa and age-related macular degeneration, from researchers at Wayne State University School of Medicine. [Genetic Engineering & Biotechnology News] Press Release Arrowhead Research Corporation Acquires Roche RNA Assets and Site Arrowhead Research Corporation announced that it has acquired RNA therapeutics assets from Roche including the state-of-the-art research site in Madison, WI. [Arrowhead Research Corporation] Press Release Cellular Dynamics International’s Human Induced Pluripotent Stem Cell (iPSC) Technology Named the Gold Winner in The Wall Street Journal 2011 Technology Innovation Awards Cellular Dynamics International announced that it was named as the overall Gold winner in The Wall Street Journal Technology Innovation Awards. [Cellular Dynamics International] Press Release UT Southwestern Biochemist Receives New NIH Early Independence Award Dr. Randal Halfmann, a research scientist at the University of Texas (UT) Southwestern Medical Center, is one of 10 investigators selected for the first National Institutes of Health (NIH) Director’s Early Independence Awards. [University of Texas Southwestern Medical Center] Press Release Roddenberry Foundation Gives $5 Million to Gladstone for Stem Cell Research The Gladstone Institutes and the Roddenberry Foundation inaugurated the Roddenberry Center for Stem Cell Biology and Medicine at Gladstone, a new unit founded on an unprecedented $5 million gift from the foundation that was established to honor the legacy of Star Trek creator Gene Roddenberry. [The J. David Gladstone Institute] Press Release Rutgers Establishes Stem Cell Repository for the Study of Mental Health Disorders Rutgers University Cell and DNA Repository has established a stem cell repository for the National Institute of Mental Health that will better enable researchers to study a variety of mental health disorders, including autism, attention deficit disorder, major depression, and schizophrenia, that affect millions of Americans. [Rutgers University] Press Release Dendreon Begins Enrolment in Phase II Neu-ACT Trial for Second Active Cellular Immunotherapy Product Candidate, DN24-02 Dendreon Corporation announced that the company has begun enrolling patients into a Phase II trial for DN24-02, Dendreon’s investigational active cellular immunotherapy being evaluated for the treatment of HER2 positive cancer. [Dendreon Corporation] Press Release Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B Oxford BioMedica plc announces that the US Food and Drug Administration has approved its Investigational New Drug (IND) application for the Phase I/IIa clinical development of UshStat®, a novel gene-based treatment for Usher syndrome type 1B. [Oxford BioMedical plc] Press Release Amsterdam Molecular Therapeutics Receives Opinion on Re-Examination of Glybera® Marketing Authorization Application Amsterdam Molecular Therapeutics announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has maintained its earlier opinion that Glybera (alipogene tiparvovec) is not approvable at this time. [Amsterdam Molecular Therapeutics] Press Release FDA Approves Continuation of ALS Stem Cell Trial Emory University researchers have received approval from the Food and Drug Administration (FDA) to advance to the next phase of a landmark trial to treat patients with Amyotrophic Lateral Sclerosis (ALS) using human neural stem cells. [Emory University] Press Release American SELICA III Trial to be Extended into Canada On September 14th, 2011 the Canadian health authority Health Canada granted Cytonet approval to extend the SELICA III trial, which has been running in the USA since 2010, into Canada. [Cytonet LLC] Press Release |